Compare UUU & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUU | CMMB |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | Israel |
| Employees | 7 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 10.5M |
| IPO Year | 2025 | 2023 |
| Metric | UUU | CMMB |
|---|---|---|
| Price | $3.50 | $1.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 10.4K | ★ 101.0K |
| Earning Date | 02-19-2026 | 05-21-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $4,847,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.88 |
| 52 Week High | $8.27 | $3.86 |
| Indicator | UUU | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 59.01 |
| Support Level | $3.02 | $1.41 |
| Resistance Level | $4.13 | $1.89 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 50.25 | 88.00 |
Universal Safety Products Inc designs and markets a variety of popularly priced safety products which, consisted mainly of smoke alarms, carbon monoxide alarms and related products. Its products require minimal installation and are designed for easy installation by the consumer without professional assistance and are sold through retail stores. It also market products to the electrical distribution trade. The electrical distribution trade includes electrical and lighting distributors as well as manufactured housing companies. Products it sell usually require professional installation. Its products are 2-in-1 Smoke & Fire Alarms, 3-in-1 Combo Alarms, and CO Alarms.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.